Androgen News and Research

RSS

Modern chemo more effective than second targeted hormone therapy against resistant prostate cancer

A modern chemotherapy drug is more effective for men with advanced prostate cancer than a second targeted hormone therapy in patients who have stopped responding to treatment, a major clinical trial shows.

30 Sep 2019

Long-term hormone therapy does more harm than good for men with low PSAs after prostate surgery

A secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer finds long-term hormone therapy does more harm than good for many men and calls for rethinking treatment guidelines based on a patient's post-operative prostate-specific antigen (PSA) level.

26 Sep 2019

Prostate cancer risk linked to assisted reproduction techniques

A study published in BMJ has revealed a link between the risk of prostate cancer and men who have become fathers via assisted reproduction techniques.

26 Sep 2019

Discovery provides potential therapeutic target for prostate cancers with PTEN mutation

PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate cancers, and in as many as 50% of androgen deprivation-resistant prostate cancers, relies on another gene, ARID4B, to function.

24 Sep 2019

U-M and Karmanos receive NCI grant to find new solutions for prostate cancer

Michigan's two elite cancer programs are joining forces to find new solutions for prostate cancer. The University of Michigan Rogel Cancer and the Barbara Ann Karmanos Cancer Institute have received a prestigious $9.2 million grant from the National Cancer Institute.

23 Sep 2019

Pre-SRT PSA could serve as prognostic and predictive biomarker of benefit from hormone therapy

Initial results of NRG Oncology Clinical Trial RTOG 9601 in men with biochemically recurrent prostate cancer receiving salvage radiotherapy demonstrated improvement in OS from the addition of long-term hormone therapy to SRT.

17 Sep 2019

FDA clears its IND for new immunotherapeutic for treating prostate cancer

Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.

21 Aug 2019

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park Comprehensive Cancer Center researchers have received more than a dozen recent grant awards totaling more than $15.4 million.

14 Aug 2019

New oral androgen deprivation therapy increases risk of death in cardiovascular patients

A new large population-based study from the Sidney Kimmel Cancer Center – Jefferson Health shows that novel oral androgen signaling inhibitor therapies are associated with an increased risk of death in patients with pre-existing cardiovascular conditions.

13 Aug 2019

Study finds attractive therapeutic target for treatment of Kennedy's disease and prostrate cancer

A study led by scientists at the Institute for Research in Biomedicine and published in Nature Communications proposes chaperone protein Hps70 as an attractive therapeutic target for the treatment of Kennedy's disease—a rare neuromuscular condition—and of castration-resistant prostate cancer.

8 Aug 2019

Estrogen exposure during fetal life increases autism risk

In a new study, scientists confirmed that babies who are exposed to higher levels of estrogen while they are in the womb are more likely to be autistic. The study titled, 'Foetal oestrogens and autism', is published in the journal, Molecular Psychiatry.

30 Jul 2019

Researchers identify key to controlling growth and progression of prostate cancer

Cancer researchers at the University of Virginia School of Medicine have identified a key to controlling the growth and progression of prostate cancer, the second most common cancer in men.

30 Jul 2019

Study reveals how aggressive prostate cancer metastasizes by evading the immune system

Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the the immune system.

18 Jul 2019

Could hormone therapy for prostate cancer increase the risk of Alzheimer’s disease?

Men who take hormone-blocking therapy (ADT) for prostate cancer may be at an increased risk of developing dementia and Alzheimer’s disease.

8 Jul 2019

Study finds new cancer driver which is fast, furious and loud

The Fast and the Furious movie franchise meets the Fast N' Loud television series to define an oncogene that drives 35% of prostate cancers.

27 Jun 2019

Novel combination therapy shown to be safe and effective for prostate cancer patients

A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2019 Annual Meeting.

26 Jun 2019

Biomarker correlates with prostate cancer aggressiveness and predicts metastasis to bone

Mortality due to prostate cancer is usually related to its likelihood to metastasize, especially to bone. Prognostic biomarkers are urgently needed to predict disease aggression so that appropriate treatment can be selected.

12 Jun 2019

International clinical study of new drug to treat advanced prostate cancers yields promising results

Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers.

3 Jun 2019

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.